Experts debate the value of the new agent for low-grade gliomas with an IDH1 or IDH2 mutation. Some have hailed the drug a “breakthrough,” whereas others call the approval “premature.”
Medscape Medical News
Vorasidenib for Certain IDH-Mutant Gliomas: Is It Worth It?
